Jarraya Faical, Lakhdar Rim, Kammoun Khawla, Mahfoudh Hichem, Drissa Habiba, Kammoun Samir, Abid Mohamed, Hachicha Jamil
Department of Nephrology, H Chaker University Hospital, Sfax, Tunisia.
Iran J Kidney Dis. 2013 May;7(3):178-86.
Leakage of small amounts of proteins in urine has been considered since 1980s a crucial sign of early kidney disease, especially in diabetic patients. An increasing interest in microalbuminuria as a cardiovascular risk marker has been more recently considered. Many studies linked microalbuminuria to early cardiovascular disease, as a marker of endothelial dysfunction, not only in diabetic patients, but also in hypertensive patients and in general population. Microalbuminuria is considered nowadays by guidelines as a cost-effective marker of subclinical organ damage in hypertensive patients and should be checked routinely in hypertensive patients. Assessing subclinical organ damage is recommended not only at the level of screening, but also during treatment. Microalbuminuria is also considered as a treatment outcome marker and useful for understanding the ability of a given therapeutic intervention to regress organ damage or slow down its progression.
自20世纪80年代以来，尿液中少量蛋白质泄漏一直被视为早期肾病的关键迹象，尤其是在糖尿病患者中。近年来，人们越来越关注微量白蛋白尿作为心血管风险标志物。许多研究不仅在糖尿病患者中，而且在高血压患者和普通人群中，将微量白蛋白尿与早期心血管疾病联系起来，作为内皮功能障碍的标志物。如今，指南将微量白蛋白尿视为高血压患者亚临床器官损伤的一种经济有效的标志物，高血压患者应定期检查。不仅在筛查阶段，而且在治疗期间，都建议评估亚临床器官损伤。微量白蛋白尿也被视为治疗结果标志物，有助于了解特定治疗干预使器官损伤消退或减缓其进展的能力。
